Carl Dambkowski Sells 4,540 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) Stock

Apogee Therapeutics, Inc. (NASDAQ:APGE) insider Carl Dambkowski sold 4,540 shares of the business’s stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $48.76, for a total transaction of $221,370.40. Following the completion of the transaction, the insider now owns 258,073 shares of the company’s stock, valued at $12,583,639.48. This represents a 1.73 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Carl Dambkowski also recently made the following trade(s):

• On Wednesday, December 4th, Carl Dambkowski sold 6,665 shares of Apogee Therapeutics stock. The stock was sold at an average price of $46.07, for a total transaction of $307,056.55.
• On Wednesday, November 6th, Carl Dambkowski sold 6,665 shares of Apogee Therapeutics stock. The shares were sold at an average price of $59.12, for a total transaction of $394,034.80.
• On Wednesday, October 2nd, Carl Dambkowski sold 6,665 shares of Apogee Therapeutics stock. The stock was sold at an average price of $56.26, for a total value of $374,972.90.

Apogee Therapeutics Stock Up 0.4 %

Shares of NASDAQ:APGE opened at $44.50 on Friday. Apogee Therapeutics, Inc. has a 52-week low of $20.78 and a 52-week high of $72.29. The stock has a market cap of $2.00 billion, a price-to-earnings ratio of -18.39 and a beta of 2.30. The business has a 50-day moving average price of $51.43 and a 200-day moving average price of $48.28.

Hedge Funds Weigh In On Apogee Therapeutics

A number of institutional investors have recently bought and sold shares of APGE. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of Apogee Therapeutics in the 3rd quarter valued at $71,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Apogee Therapeutics by 21.2% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,628 shares of the company’s stock valued at $94,000 after purchasing an additional 285 shares during the last quarter. Allspring Global Investments Holdings LLC acquired a new stake in Apogee Therapeutics during the 2nd quarter worth about $143,000. Wexford Capital LP purchased a new position in shares of Apogee Therapeutics during the 3rd quarter valued at about $230,000. Finally, Arizona State Retirement System lifted its holdings in shares of Apogee Therapeutics by 4.5% in the 2nd quarter. Arizona State Retirement System now owns 5,993 shares of the company’s stock valued at $236,000 after buying an additional 258 shares during the period. 79.04% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the company. Wedbush boosted their target price on Apogee Therapeutics from $87.00 to $90.00 and gave the stock an “outperform” rating in a research note on Monday, December 2nd. Canaccord Genuity Group began coverage on Apogee Therapeutics in a research note on Monday, November 25th. They set a “buy” rating and a $89.00 price target on the stock. Canaccord Genuity Group initiated coverage on shares of Apogee Therapeutics in a research report on Monday, November 25th. They issued a “buy” rating and a $89.00 price objective for the company. Finally, Guggenheim reiterated a “buy” rating on shares of Apogee Therapeutics in a research note on Thursday. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Apogee Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $83.88.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.